Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Arbutus Biopharma: LNP Litigation And Imdusiran Drive Near-Term Catalysts
Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
Arbutus (ABUS) Q2 Revenue Surges 529%
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates
Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
GE HealthCare launches AI-driven, patient-friendly Invenia ABUS Premium to accelerate scanning and drive early cancer detection in dense breasts
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.
Arbutus Provides 2025 Corporate and Financial Update
Arbutus: Positive Imdusiran Data Leads To Phase 2B Development
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Arbutus to Present at Jefferies London Healthcare Conference
Arbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call Transcript
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year?
Arbutus to Participate in Two Upcoming Investor Conferences
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
Arbutus Layoffs 2024: What to Know About the Latest ABUS Job Cuts
Arbutus Biopharma Corporation (ABUS) Q2 2024 Earnings Call Transcript
Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update